Drugs / Tuvorilimab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07310069 | May 2025 → May 2027 expected | gallbladder cancer | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tuvorilimab | “Iparomlimab and Tuvorilimab (a dual anti-PD-1/CTLA-4 bispecific antibody)” NCT07310069 ↗ |
| Action | Inhibit | “a dual anti-PD-1/CTLA-4 bispecific antibody” NCT07310069 ↗ |